R-Biopharm AG Enters Into a Strategic Alliance with CANDOR Bioscience GmbH
Seamless chain of competence from biomarkers to market-ready Companion Diagnostics for research-driven pharmaceutical and biotech companies.
(firmenpresse) - R-Biopharm, a global leader in providing innovative clinical diagnostics, enters into a strategic alliance with CANDOR Bioscience GmbH (Wangen, Allgäu, Germany), effective immediately.
R-Biopharm has its own corporate division for companion diagnostics (CDx), i.e. diagnostics concomitant to therapy, as well as for complementary diagnostics. There, R-Biopharm is at the spearhead of the current development of tests for new approaches in personalized medicine.
R-Biopharm will further expand its position by means of an intensive co-operation with CANDOR: CANDOR has already carried out a large number of successful assay projects for university research clients, diagnostics manufacturers and leading pharmaceutical companies.
Thanks to their co-operation, R-Biopharm and CANDOR will be able to streamline the overall development process for immunological and phenotypical biomarkers while controlling the entire process chain – from the first research approach via pre-clinical and clinical phases all the way to the validated, approved and authorized diagnostic product.
Thus, important contributions to personalized medicine will be faster and more effective, and they will be more readily available for patients worldwide thanks to the R-Biopharm marketing competence.
Partners from the pharmaceutical and biotech industries are thus able to focus on developing medication, knowing they have a partner at their side that provides twofold diagnostic strength, across the entire project duration – including development, validation, regulatory approval and authorization, production and marketing of companion diagnostics assays.
Complementary Diagnostics
Complementary diagnostics represents an important move towards the convergence of in vitro diagnostics and therapeutics. Complementary diagnostics does not require a strict drug/diagnostic regulatory link at the time of development – thus opening up great new ways of research into in vitro diagnostics and its impact on therapeutics. The concept of complementary diagnostics also includes diagnostics concomitant to therapy (companion diagnostics), thus opening new opportunities, ensuring values and generating a competitive edge for pharmaceutical and biotech companies. The market share of already approved pharmaceuticals may sometimes be increased by complementary diagnostics. At the same time, the proportion of non-responders can be reduced in many cases. Side effects can sometimes be avoided altogether, so that the benefit and thus the value of pharmaceuticals can be increased also from a healthcare cost payer perspective.
www.companion-diagnostics.com
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
R-Biopharm AG
R-Biopharm AG (Darmstadt, Germany) is a globally active life science company and a leading provider of reliable test systems for clinical diagnostics and for analyzing human food and animal feedstuffs. Since 1988, R-Biopharm has been developing innovative products characterized by top quality, reliability and efficiency. A strong sense of responsibility, long-standing experience and a network of 21 affiliated companies and subsidiaries in the US, Europe, South America, China and Australia, as well as more than 100 distribution partners, make R-Biopharm a prime address for clients from retail, industry and public institutions looking for answers and solutions for current analytical challenges.
www.r-biopharm.com
CANDOR Bioscience GmbH
CANDOR Bioscience GmbH is an international company for the development, production and distribution of a comprehensive selection of premium solutions for immunoassays. CANDOR offers more than 50 different products including optimizers, blockers, stabilizers and buffers for immunoassays. By using these solutions the reliability of results can be improved, the assay can be simplified and process times can be reduced. Manufacturing is exclusively done by CANDOR itself, thus controlling all aspects of product quality.
www.candor-bioscience.com
CANDOR Bioscience GmbH
Dr. Sabine Glöggler
Simoniusstrasse 39
88239 Wangen, Germany
s.gloeggler(at)candor-bioscience.com
www.candor-bioscience.com
R-Biopharm AG
Personalized Healthcare
Dr. Frank Apostel, Director of Business Development
An der neuen Bergstraße 17
64297 Darmstadt, Germany
f.apostel(at)r-biopharm.de
www.companion-diagnostics.com
CANDOR Bioscience GmbH
Dr. Sabine Glöggler
Simoniusstrasse 39
88239 Wangen, Germany
s.gloeggler(at)candor-bioscience.com
www.candor-bioscience.com
R-Biopharm AG
Personalized Healthcare
Dr. Frank Apostel, Director of Business Development
An der neuen Bergstraße 17
64297 Darmstadt, Germany
f.apostel(at)r-biopharm.de
www.companion-diagnostics.com
Datum: 13.11.2013 - 11:29 Uhr
Sprache: Deutsch
News-ID 315804
Anzahl Zeichen: 2863
contact information:
Contact person: Josef Goetz
Town:
Wangen
Phone: 0049-7732-919331
Kategorie:
Healthcare & Medical
Typ of Press Release: Unternehmensinformation
type of sending: Veröffentlichung
Diese Pressemitteilung wurde bisher 547 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"R-Biopharm AG Enters Into a Strategic Alliance with CANDOR Bioscience GmbH"
steht unter der journalistisch-redaktionellen Verantwortung von
CANDOR Bioscience GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
